Exelixis, Inc. (EXEL)
54.62
+0.17
(+0.31%)
USD |
NASDAQ |
Aug 31, 16:00
54.70
+0.08
(+0.15%)
After-Hours: 20:00
Exelixis Cash from Operations (TTM) : 1.183B for June 30, 2026
Cash from Operations (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 1.183B |
| March 31, 2026 | 924.68M |
| December 31, 2025 | 884.27M |
| September 30, 2025 | 791.02M |
| June 30, 2025 | 772.03M |
| March 31, 2025 | 842.59M |
| December 31, 2024 | 699.97M |
| September 30, 2024 | 470.28M |
| June 30, 2024 | 316.31M |
| March 31, 2024 | 317.74M |
| December 31, 2023 | 333.32M |
| September 30, 2023 | 396.45M |
| June 30, 2023 | 389.15M |
| March 31, 2023 | 299.30M |
| December 31, 2022 | 362.61M |
| September 30, 2022 | 385.37M |
| June 30, 2022 | 358.61M |
| March 31, 2022 | 508.98M |
| December 31, 2021 | 400.80M |
| September 30, 2021 | 337.64M |
| June 30, 2021 | 272.28M |
| March 31, 2021 | 192.45M |
| December 31, 2020 | 208.98M |
| September 30, 2020 | 333.71M |
| June 30, 2020 | 391.39M |
| Date | Value |
|---|---|
| March 31, 2020 | 421.44M |
| December 31, 2019 | 526.96M |
| September 30, 2019 | 473.53M |
| June 30, 2019 | 562.46M |
| March 31, 2019 | 505.50M |
| December 31, 2018 | 415.72M |
| September 30, 2018 | 364.48M |
| June 30, 2018 | 237.80M |
| March 31, 2018 | 168.56M |
| December 31, 2017 | 165.61M |
| September 30, 2017 | 195.97M |
| June 30, 2017 | 149.61M |
| March 31, 2017 | 118.34M |
| December 31, 2016 | 206.30M |
| September 30, 2016 | 87.15M |
| June 30, 2016 | 61.41M |
| March 31, 2016 | 60.31M |
| December 31, 2015 | -141.58M |
| September 30, 2015 | -156.13M |
| June 30, 2015 | -179.90M |
| March 31, 2015 | -208.40M |
| December 31, 2014 | -235.40M |
| September 30, 2014 | -232.76M |
| June 30, 2014 | -231.75M |
| March 31, 2014 | -216.44M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (TTM) Benchmarks
| Alnylam Pharmaceuticals, Inc. | 885.89M |
| BioMarin Pharmaceutical, Inc. | 857.09M |
| Cytokinetics, Inc. | -555.45M |
| Emergent BioSolutions, Inc. | 97.70M |
| Gilead Sciences, Inc. | 13.55B |